Ridgeback Capital — Full Portfolio

Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.

BiotechHealthtechMedical Devices

Co-investorsAvoro Capital AdvisorsEight Roads VenturesF-Prime CapitalNew Enterprise Associates (NEA)

Co-investorsVedanta Capital

Cellectis develops proprietary gene-editing technologies for applications in immuno-oncology and plant sciences to address medical and food needs.

AgTechAI & Machine LearningBiotechDeep TechHealthtech

Patrick Mahaffy(Founder)in

Co-investorsAisling CapitalNew Enterprise Associates (NEA)

Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.

BiotechDigital HealthHealthtechMedical DevicesFoster City, US

Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin

Co-investorsAisling CapitalAsset Management CompanyFrazier Life SciencesKleiner PerkinsLongitude CapitalLumira Ventures+5 more

Victoria Richonin

Co-investorsKleiner Perkins

Kyntra Bio (formerly FibroGen) is a clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases, including serious and life-threatening conditions.

BiotechHealthtechSan Francisco, US

Thomas B. Neff(Executive Officer, Director)Frank H. Valone(Executive Officer)K. Peony Yu(Executive Officer)Pat Cotroneo(Executive Officer)

BoardRory B. Riggs(Director)Kalevi Kurkijarvi(Director)

Co-investorsAvalon BioVenturesScientia VenturesMaverick Ventures

GENFIT is a biopharmaceutical company developing therapies for rare, life-threatening liver diseases, with an R&D pipeline of eight programs focused on acute-on-chronic liver failure, hepatic encephalopathy, cholangiocarcinoma, and urea cycle disorders/organic acidemias.

BiotechHealthtech

Co-investorsredalpine

Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects.

BiotechHealthtechBurlingame, US

Daniel J. Capon(Director)Carin M. Rollins(Executive Officer, Director)Carin Mueller Rollins(Co-Founder & Chief Operating Officer)Harold E. Selick, PhD(Executive Officer, Director)Miriam Siekevitz(Executive Officer)Harold E. "Barry" Selick(Chief Executive Officer & Director)

Co-investorsPoint72Baruch Future VenturesInVivium CapitalAgent Capital

Intercept Pharma develops therapeutics for rare liver diseases, focusing on cholestatic pruritus in Primary Biliary Cholangitis patients through IBAT inhibitor programs and bile acid biology research.

BiotechHealthtechMedical Devices

Co-investorsAisling CapitalBioBritSamsara BioCapital

Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing treatments for GI diseases.

BiotechDigital HealthHealthtechCambridge, US

PETER M. HECHT(Executive Officer, Director)MARK G. CURRIE(Executive Officer)HALLEY E. GIBLERT(Executive Officer)THOMAS GRANEY(Executive Officer)THOMAS A. MCCOURT(Executive Officer)

BoardTERRANCE G. MCGUIRE(Director)

Co-investorsF-Prime CapitalMountain Group CapitalVenrockMaverick VenturesPolaris Partners

Regeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease.

BiotechHealthtechTarrytown, US

Co-investorsSanderling VenturesvenBio PartnersWireframe Ventures

Sangamo is a genomic medicine company using its proprietary zinc finger technology to develop gene therapies aimed at curing severe diseases, with a focus on neurology and rare disorders.

BiotechMedical Devices

Co-investorsCalifornia Technology VenturesFoothill VenturesForesite Capital

Co-investorsArtis VenturesThe Column Group

Co-investorsKleiner PerkinsSofinnova Ventures